We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

143 hedge funds and large institutions have $124M invested in Nektar Therapeutics in 2024 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 49 increasing their positions, 35 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,260% more call options, than puts

Call options by funds: $218K | Put options by funds: $5K

40% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 35

31% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 16

4% more funds holding

Funds holding: 138 → 143 (+5)

0.3% less ownership

Funds ownership: 5.1% → 4.8% (-0.3%)

32% less capital invested

Capital invested by funds: $183M → $124M (-$59.4M)

Holders
143
Holders Change
+5
Holders Change %
+3.62%
% of All Funds
1.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
49
Reduced
35
Closed
16
Calls
$218K
Puts
$5K
Net Calls
+$213K
Net Calls Change
+$54K

Top Buyers

1
NCM
Nantahala Capital Management
Connecticut
+$4.35M
2
WP
Woodline Partners
California
+$3.81M
3
ACM
Altium Capital Management
New York
+$3.51M
4
2L
22NW LP
Washington
+$2.58M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.82M

Top Sellers

1
DTC
Deep Track Capital
Connecticut
-$16.4M
2
Citadel Advisors
Citadel Advisors
Florida
-$7.71M
3
EAM
Eventide Asset Management
Massachusetts
-$3.23M
4
SC
Shay Capital
New York
-$1.46M
5
AI
Acuitas Investments
Washington
-$1.43M
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$1.1M +$317K +17,979 +30%
PLC
27
Peapod Lane Capital
New York
$1.03M +$1.3M +73,834 New
AC
28
Armistice Capital
New York
$952K +$28.2K +1,600 +2%
AC
29
Almitas Capital
California
$856K – – –
AQR Capital Management
30
AQR Capital Management
Connecticut
$775K +$390K +22,111 +66%
Morgan Stanley
31
Morgan Stanley
New York
$746K +$66.1K +3,748 +8%
CM
32
CM Management
Florida
$698K – – –
Connor, Clark & Lunn Investment Management (CC&L)
33
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$680K +$94.1K +5,336 +12%
Goldman Sachs
34
Goldman Sachs
New York
$676K -$1.24M -70,404 -59%
DP
35
Diadema Partners
New Jersey
$650K +$822K +46,595 New
Invesco
36
Invesco
Georgia
$610K +$10.2K +581 +1%
EAM
37
Exome Asset Management
New York
$575K +$727K +41,212 New
BFM
38
Boothbay Fund Management
New York
$517K +$243K +13,793 +59%
Wellington Management Group
39
Wellington Management Group
Massachusetts
$486K +$58K +3,288 +10%
Fidelity Investments
40
Fidelity Investments
Massachusetts
$478K +$150K +8,514 +33%
Dimensional Fund Advisors
41
Dimensional Fund Advisors
Texas
$459K -$12.5K -706 -2%
Mackenzie Financial
42
Mackenzie Financial
Ontario, Canada
$437K +$491K +27,843 +801%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$382K – – –
Citadel Advisors
44
Citadel Advisors
Florida
$369K -$7.71M -437,196 -94%
Ameriprise
45
Ameriprise
Minnesota
$348K +$109K +6,157 +33%
SC
46
Shay Capital
New York
$328K -$1.46M -82,872 -78%
N
47
Nuveen
North Carolina
$304K – – –
Barclays
48
Barclays
United Kingdom
$303K -$38.2K -2,165 -9%
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
$291K +$86.8K +4,923 +31%
UBS Group
50
UBS Group
Switzerland
$285K +$227K +12,894 +172%
1
2
3 4 5

NKTR Hedge Fund Activity: Q4 2024 in Review

143 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q4 2024, worth a combined $124M — down 32% from $183M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new NKTR positions and 16 closed out — a net gain of 5 holders — while 49 added to existing stakes and 35 trimmed.

The largest buyer was Nantahala Capital Management, adding an estimated $4.35M. The largest seller was Deep Track Capital, cutting an estimated $16.4M.

  • 143 institutional investors held Nektar Therapeutics (NKTR) as of Q4 2024, up from 138 in Q3 2024.
  • Funds reported $124M of Nektar Therapeutics stock for Q4 2024, down 32% quarter-over-quarter.
  • 21 funds opened new Nektar Therapeutics positions in Q4 2024 and 16 closed out, a net change of +5 holders.
  • The largest Nektar Therapeutics buyer in Q4 2024 was Nantahala Capital Management, an estimated $4.35M added.
  • The largest Nektar Therapeutics seller in Q4 2024 was Deep Track Capital, an estimated $16.4M sold.

Based on aggregated 13F filings for Q4 2024.